Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

High FGF21 levels are associated with altered bone homeostasis in HIV-1-infected patients.

Gallego-Escuredo JM, Lamarca MK, Villarroya J, Domingo JC, Mateo MG, Gutierrez MDM, Vidal F, Villarroya F, Domingo P, Giralt M.

Metabolism. 2017 Jun;71:163-170. doi: 10.1016/j.metabol.2017.03.014. Epub 2017 Mar 31.

PMID:
28521869
2.

Hydrodynamics of defecation.

Yang PJ, LaMarca M, Kaminski C, Chu DI, Hu DL.

Soft Matter. 2017 Jul 26;13(29):4960-4970. doi: 10.1039/c6sm02795d.

PMID:
28470247
3.

Circulating fibroblast growth factor 23 (FGF23) levels are associated with metabolic disturbances and fat distribution but not cardiovascular risk in HIV-infected patients.

Domingo P, Lamarca MK, Gallego-Escuredo JM, Torres F, Domingo JC, Villarroya J, Gutierrez Mdel M, Mateo MG, Vidal F, Villarroya F, Giralt M.

J Antimicrob Chemother. 2015;70(6):1825-32. doi: 10.1093/jac/dkv027. Epub 2015 Feb 19.

PMID:
25700720
4.

[Assessment of the reliability of food labeling in Chile].

Urquiaga I, Lamarca M, Jiménez P, Echeverría G, Leighton F.

Rev Med Chil. 2014 Jun;142(6):775-81. doi: 10.4067/S0034-98872014000600012. Spanish.

5.

Neuroinflammation and α-synuclein accumulation in response to glucocerebrosidase deficiency are accompanied by synaptic dysfunction.

Ginns EI, Mak SK, Ko N, Karlgren J, Akbarian S, Chou VP, Guo Y, Lim A, Samuelsson S, LaMarca ML, Vazquez-DeRose J, Manning-Boğ AB.

Mol Genet Metab. 2014 Feb;111(2):152-62. doi: 10.1016/j.ymgme.2013.12.003. Epub 2013 Dec 11.

PMID:
24388731
6.

Leiomyomatosis peritonealis disseminata with malignant degeneration. A case report.

Lamarca M, Rubio P, Andrés P, Rodrigo C.

Eur J Gynaecol Oncol. 2011;32(6):702-4.

PMID:
22335043
7.

Ethinylestradiol/Chlormadinone acetate for use in dermatological disorders.

Gómez Vázquez M, Navarra Amayuelas R, Lamarca M, Baquedano L, Romero Ruiz S, Vilar-Checa E, Iniesta MD.

Am J Clin Dermatol. 2011 Sep 6;12 Suppl 1:13-9. doi: 10.2165/1153875-S0-000000000-00000.

PMID:
21895045
8.

Subcapital fracture of the hip in transient osteoporosis of pregnancy.

Lamarca M, Hernandez M, Campillos JM, Lapresta M, Tobajas JJ.

Taiwan J Obstet Gynecol. 2009 Dec;48(4):423-4. doi: 10.1016/S1028-4559(09)60337-5. No abstract available.

9.

In silico and functional studies of the regulation of the glucocerebrosidase gene.

Blech-Hermoni YN, Ziegler SG, Hruska KS, Stubblefield BK, Lamarca ME, Portnoy ME; NISC Comparative Sequencing Program, Green ED, Sidransky E.

Mol Genet Metab. 2010 Mar;99(3):275-82. doi: 10.1016/j.ymgme.2009.10.189. Epub 2009 Nov 4.

10.

Lysosomal storage disorders in the newborn.

Staretz-Chacham O, Lang TC, LaMarca ME, Krasnewich D, Sidransky E.

Pediatrics. 2009 Apr;123(4):1191-207. doi: 10.1542/peds.2008-0635. Review.

11.

Optimization and validation of two miniaturized glucocerebrosidase enzyme assays for high throughput screening.

Urban DJ, Zheng W, Goker-Alpan O, Jadhav A, Lamarca ME, Inglese J, Sidransky E, Austin CP.

Comb Chem High Throughput Screen. 2008 Dec;11(10):817-24.

12.

Leiomyomas in both uterine remnants in a woman with the Mayer-Rokitansky-Küster-Hauser syndrome.

Lamarca M, Navarro R, Ballesteros ME, García-Aguirre S, Conte MP, Duque JA.

Fertil Steril. 2009 Mar;91(3):931.e13-5. doi: 10.1016/j.fertnstert.2008.08.132. Epub 2008 Oct 18.

PMID:
18930201
13.

The need for appropriate genotyping strategies for glucocerebrosidase mutations in cohorts with Parkinson disease.

Gutti U, Fung HC, Hruska KS, Lamarca ME, Chen CM, Wu YR, Sidransky E.

Arch Neurol. 2008 Jun;65(6):850-1; author reply 851. doi: 10.1001/archneur.65.6.850. No abstract available.

14.

Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA).

Hruska KS, LaMarca ME, Scott CR, Sidransky E.

Hum Mutat. 2008 May;29(5):567-83. doi: 10.1002/humu.20676. Review.

PMID:
18338393
15.

Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease.

Zheng W, Padia J, Urban DJ, Jadhav A, Goker-Alpan O, Simeonov A, Goldin E, Auld D, LaMarca ME, Inglese J, Austin CP, Sidransky E.

Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13192-7. Epub 2007 Aug 1.

16.

Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease.

Ziegler SG, Eblan MJ, Gutti U, Hruska KS, Stubblefield BK, Goker-Alpan O, LaMarca ME, Sidransky E.

Mol Genet Metab. 2007 Jun;91(2):195-200. Epub 2007 Apr 25.

17.

Therapy for Gaucher disease: don't stop thinking about tomorrow.

Sidransky E, LaMarca ME, Ginns EI.

Mol Genet Metab. 2007 Feb;90(2):122-5. Epub 2006 Nov 3. Review.

PMID:
17084653
18.

Gaucher mutation N188S is associated with myoclonic epilepsy.

Kowarz L, Goker-Alpan O, Banerjee-Basu S, LaMarca ME, Kinlaw L, Schiffmann R, Baxevanis AD, Sidransky E.

Hum Mutat. 2005 Sep;26(3):271-3; author reply 274-5.

PMID:
16086325
19.

Parkinsonism among Gaucher disease carriers.

Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E.

J Med Genet. 2004 Dec;41(12):937-40.

20.

A novel alteration in metaxin 1, F202L, is associated with N370S in Gaucher disease.

LaMarca ME, Goldstein M, Tayebi N, Arcos-Burgos M, Martin BM, Sidransky E.

J Hum Genet. 2004;49(4):220-2. Epub 2004 Mar 13.

PMID:
15024629
21.

Glucocerebrosidase mutations in subjects with parkinsonism.

Lwin A, Orvisky E, Goker-Alpan O, LaMarca ME, Sidransky E.

Mol Genet Metab. 2004 Jan;81(1):70-3.

PMID:
14728994
22.

Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?

Tayebi N, Walker J, Stubblefield B, Orvisky E, LaMarca ME, Wong K, Rosenbaum H, Schiffmann R, Bembi B, Sidransky E.

Mol Genet Metab. 2003 Jun;79(2):104-9.

PMID:
12809640
23.

Glucocerebrosidase mutation T369M appears to be another polymorphism.

Walker JM, Lwin A, Tayebi N, LaMarca ME, Orvisky E, Sidransky E.

Clin Genet. 2003 Mar;63(3):237-8. No abstract available.

PMID:
12694238
24.

Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup.

Park JK, Orvisky E, Tayebi N, Kaneski C, Lamarca ME, Stubblefield BK, Martin BM, Schiffmann R, Sidransky E.

Pediatr Res. 2003 Mar;53(3):387-95.

PMID:
12595585
25.

Reciprocal and nonreciprocal recombination at the glucocerebrosidase gene region: implications for complexity in Gaucher disease.

Tayebi N, Stubblefield BK, Park JK, Orvisky E, Walker JM, LaMarca ME, Sidransky E.

Am J Hum Genet. 2003 Mar;72(3):519-34. Epub 2003 Feb 13.

26.

Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: correlation with phenotype and genotype.

Orvisky E, Park JK, LaMarca ME, Ginns EI, Martin BM, Tayebi N, Sidransky E.

Mol Genet Metab. 2002 Aug;76(4):262-70.

PMID:
12208131
27.

The E326K mutation and Gaucher disease: mutation or polymorphism?

Park JK, Tayebi N, Stubblefield BK, LaMarca ME, MacKenzie JJ, Stone DL, Sidransky E.

Clin Genet. 2002 Jan;61(1):32-4.

PMID:
11903352
28.

Glucosylsphingosine accumulation in mice and patients with type 2 Gaucher disease begins early in gestation.

Orvisky E, Sidransky E, McKinney CE, Lamarca ME, Samimi R, Krasnewich D, Martin BM, Ginns EI.

Pediatr Res. 2000 Aug;48(2):233-7.

PMID:
10926300
29.

Targeted reduction of oxytocin expression provides insights into its physiological roles.

Young WS 3rd, Shepard E, DeVries AC, Zimmer A, LaMarca ME, Ginns EI, Amico J, Nelson RJ, Hennighausen L, Wagner KU.

Adv Exp Med Biol. 1998;449:231-40.

PMID:
10026810
30.

Monitoring the CNS pathology in aspartylglucosaminuria mice.

Tenhunen K, Uusitalo A, Autti T, Joensuu R, Kettunen M, Kauppinen RA, Ikonen S, LaMarca ME, Haltia M, Ginns EI, Jalanko A, Peltonen L.

J Neuropathol Exp Neurol. 1998 Dec;57(12):1154-63.

PMID:
9862638
31.

Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II.

Raben N, Nagaraju K, Lee E, Kessler P, Byrne B, Lee L, LaMarca M, King C, Ward J, Sauer B, Plotz P.

J Biol Chem. 1998 Jul 24;273(30):19086-92.

32.

Mice with an aspartylglucosaminuria mutation similar to humans replicate the pathophysiology in patients.

Jalanko A, Tenhunen K, McKinney CE, LaMarca ME, Rapola J, Autti T, Joensuu R, Manninen T, Sipilä I, Ikonen S, Riekkinen P Jr, Ginns EI, Peltonen L.

Hum Mol Genet. 1998 Feb;7(2):265-72.

PMID:
9425233
33.

Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis.

Kyriakides TR, Zhu YH, Smith LT, Bain SD, Yang Z, Lin MT, Danielson KG, Iozzo RV, LaMarca M, McKinney CE, Ginns EI, Bornstein P.

J Cell Biol. 1998 Jan 26;140(2):419-30.

34.

Deficiency in mouse oxytocin prevents milk ejection, but not fertility or parturition.

Young WS 3rd, Shepard E, Amico J, Hennighausen L, Wagner KU, LaMarca ME, McKinney C, Ginns EI.

J Neuroendocrinol. 1996 Nov;8(11):847-53.

PMID:
8933362
35.

Metaxin, a gene contiguous to both thrombospondin 3 and glucocerebrosidase, is required for embryonic development in the mouse: implications for Gaucher disease.

Bornstein P, McKinney CE, LaMarca ME, Winfield S, Shingu T, Devarayalu S, Vos HL, Ginns EI.

Proc Natl Acad Sci U S A. 1995 May 9;92(10):4547-51.

36.

A biochemical and ultrastructural evaluation of the type 2 Gaucher mouse.

Willemsen R, Tybulewicz V, Sidransky E, Eliason WK, Martin BM, LaMarca ME, Reuser AJ, Tremblay M, Westphal H, Mulligan RC, et al.

Mol Chem Neuropathol. 1995 Feb-Apr;24(2-3):179-92.

PMID:
7632321
37.

Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene.

Tybulewicz VL, Tremblay ML, LaMarca ME, Willemsen R, Stubblefield BK, Winfield S, Zablocka B, Sidransky E, Martin BM, Huang SP, et al.

Nature. 1992 Jun 4;357(6377):407-10.

PMID:
1594045
38.

Brain grafts and Parkinson's disease.

Freed WJ, Poltorak M, Takashima H, LaMarca ME, Ginns EI.

J Cell Biochem. 1991 Mar;45(3):261-7. Review.

PMID:
2066376
39.

Genetically altered and defined cell lines for transplantation in animal models of Parkinson's disease.

Freed WJ, Geller HM, Poltorak M, Cannon-Spoor HE, Cottingham SL, LaMarca ME, Schultzberg M, Rehavi M, Paul S, Ginns EI.

Prog Brain Res. 1990;82:11-21. Review. No abstract available.

PMID:
1981273
40.

Expression of human tyrosine hydroxylase cDNA in invertebrate cells using a baculovirus vector.

Ginns EI, Rehavi M, Martin BM, Weller M, O'Malley KL, LaMarca ME, McAllister CG, Paul SM.

J Biol Chem. 1988 May 25;263(15):7406-10.

41.

Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals.

Tsuji S, Martin BM, Barranger JA, Stubblefield BK, LaMarca ME, Ginns EI.

Proc Natl Acad Sci U S A. 1988 Apr;85(7):2349-52. Erratum in: Proc Natl Acad Sci U S A 1988 Aug;85(15):5708.

42.
43.
44.

Retrovirus-mediated transfer of the human glucocerebrosidase gene to Gaucher fibroblasts.

Choudary PV, Barranger JA, Tsuji S, Mayor J, LaMarca ME, Cepko CL, Mulligan RC, Ginns EI.

Mol Biol Med. 1986 Jun;3(3):293-9.

PMID:
3736391
45.

Gonadotropins and the timing of progesterone-induced meiotic maturation of Xenopus laevis oocytes.

LaMarca MJ, Westphal LM, Rein DA.

Dev Biol. 1985 May;109(1):32-40.

PMID:
3987966
46.

Demonstration of remarkable sequence divergence in variants of a complex satellite DNA by molecular cloning.

Stringfellow LA, Fowler RF, LaMarca ME, Skinner DM.

Gene. 1985;38(1-3):145-52.

PMID:
3905513
48.
49.

Effects of 4-aminopyridine on the cat superior cervical ganglion.

Lamarca MV, Collier B.

J Pharmacol Exp Ther. 1983 Jul;226(1):249-57.

PMID:
6864543
50.

Supplemental Content

Loading ...
Support Center